Skip to main content

Table 2 Randomized clinical trial study characteristics

From: Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies

Study Number of patients Mean age (years) Outcome measurea CYC treatment Placebo/alternative treatment Corticosteroid Length of follow-up (months)
Hoyles and colleagues [10] 45 55 FVC, 80.1 ± 10.3 Intravenous, 600 mg/m2 monthly Placebo Prednisone 20 mg alternate days 12
    DLCO, 52.9 ± 1.6     
Nadashkevich and colleagues [11] 60 38 to 36 FVC, 90.3 ± 1.9 Oral, 2 mg/kg/day monthly AZA 2.5 mg/kg Prednisolone 15 mg/day 12
    DLCO, 83.5 ± 1.6     
Tashkin and colleagues [1] 158 47.9 ± 1.0 FVC, 67.6 ± 1.3 Oral, 1 mg/kg/day Placebo None 12
    DLCO, 47.2 ± 1.6     
  1. Data presented as mean ± standard deviation. AZA, azathioprine; CYC, cyclophosphamide; DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity. aPercentage predicted value at baseline.